Holen Sie sich die Stockscreener-App
156.90
0.51%
-0.80
Überblick
Nachrichten
Preisverlauf
Optionskette
Warum fällt AZN?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$157.70
Offen:
$158.46
24-Stunden-Volumen:
2.64M
Relative Volume:
0.79
Marktkapitalisierung:
$243.34B
Einnahmen:
$60.48B
Nettoeinkommen (Verlust:
$10.40B
KGV:
47.12
EPS:
3.3297
Netto-Cashflow:
$8.05B
1W Leistung:
-5.81%
1M Leistung:
-2.93%
6M Leistung:
-22.90%
1J Leistung:
+87.57%
1-Tages-Spanne:
$156.41
$158.79
1-Wochen-Bereich:
$156.41
$167.52
52-Wochen-Spanne:
$80.48
$212.71
Astrazeneca Plc Stock (AZN) Company Profile
Compare AZN vs LLY, JNJ, ABBV, MRK, NVS
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AZN
Astrazeneca Plc
|
156.90 | 244.58B | 60.48B | 10.40B | 8.05B | 3.3297 |
LLY
Lilly Eli Co
|
1,142.85 | 1.02T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
256.03 | 623.34B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
262.82 | 459.33B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
144.30 | 354.80B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
141.00 | 268.10B | 54.66B | 13.58B | 16.05B | 7.0171 |
Astrazeneca Plc Stock (AZN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-27 | Eingeleitet | Citigroup | Buy |
| 2025-10-27 | Fortgesetzt | Jefferies | Buy |
| 2025-10-16 | Herabstufung | Deutsche Bank | Hold → Sell |
| 2025-04-15 | Eingeleitet | Exane BNP Paribas | Outperform |
| 2025-02-13 | Hochstufung | UBS | Neutral → Buy |
| 2025-02-12 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-11-20 | Hochstufung | UBS | Sell → Neutral |
| 2024-11-06 | Hochstufung | Deutsche Bank | Sell → Hold |
| 2024-09-13 | Herabstufung | Deutsche Bank | Hold → Sell |
| 2024-05-30 | Eingeleitet | Goldman | Buy |
| 2024-04-16 | Hochstufung | Deutsche Bank | Sell → Hold |
| 2024-02-08 | Herabstufung | Deutsche Bank | Hold → Sell |
| 2024-01-23 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-01-16 | Fortgesetzt | UBS | Sell |
| 2024-01-03 | Herabstufung | Jefferies | Buy → Hold |
| 2023-12-18 | Eingeleitet | HSBC Securities | Buy |
| 2023-09-25 | Hochstufung | Jefferies | Hold → Buy |
| 2023-07-14 | Eingeleitet | HSBC Securities | Buy |
| 2023-07-12 | Hochstufung | UBS | Neutral → Buy |
| 2023-07-05 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2023-04-11 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2023-01-05 | Eingeleitet | BMO Capital Markets | Outperform |
| 2022-09-15 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2022-09-07 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-08-29 | Hochstufung | Argus | Hold → Buy |
| 2022-06-14 | Herabstufung | UBS | Buy → Neutral |
| 2022-02-11 | Hochstufung | DZ Bank | Sell → Hold |
| 2021-12-07 | Herabstufung | Jefferies | Buy → Hold |
| 2021-08-12 | Fortgesetzt | JP Morgan | Overweight |
| 2021-04-12 | Herabstufung | Argus | Buy → Hold |
| 2021-03-16 | Hochstufung | Jefferies | Hold → Buy |
| 2021-02-25 | Hochstufung | UBS | Neutral → Buy |
| 2021-01-15 | Eingeleitet | Deutsche Bank | Buy |
| 2020-12-07 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-11-30 | Hochstufung | UBS | Sell → Neutral |
| 2020-11-11 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2020-09-29 | Eingeleitet | Berenberg | Buy |
| 2019-11-22 | Eingeleitet | SVB Leerink | Outperform |
| 2019-10-25 | Hochstufung | Liberum | Hold → Buy |
| 2019-04-02 | Herabstufung | UBS | Neutral → Sell |
| 2019-02-05 | Eingeleitet | Exane BNP Paribas | Outperform |
| 2019-01-25 | Hochstufung | Shore Capital | Hold → Buy |
| 2018-12-11 | Fortgesetzt | Jefferies | Hold |
| 2018-10-09 | Eingeleitet | Guggenheim | Buy |
| 2018-08-16 | Herabstufung | Jefferies | Buy → Hold |
| 2018-03-19 | Hochstufung | Jefferies | Hold → Buy |
| 2018-02-06 | Bestätigt | Leerink Partners | Mkt Perform |
| 2018-02-05 | Bestätigt | Bernstein | Outperform |
| 2018-01-18 | Bestätigt | Leerink Partners | Mkt Perform |
| 2017-12-29 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2017-10-16 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2017-09-25 | Hochstufung | Exane BNP Paribas | Neutral → Outperform |
| 2017-09-22 | Hochstufung | Bernstein | Mkt Perform → Outperform |
Alle ansehen
Astrazeneca Plc Aktie (AZN) Neueste Nachrichten
AstraZeneca stock after-hours at EUR 141.75: minus 1.05 percent versus prior close - AD HOC NEWS
Employee schemes bring 9,828 new AstraZeneca (AZN) shares to London Stock Exchange trading. - Stock Titan
With no treasury shares, AstraZeneca (AZN) reports 1.55B voting rights. - Stock Titan
AstraZeneca Adds Employee Scheme Shares to London Listing - TipRanks
REGAstraZeneca PLCAdmission of Further Securities to Trading - TradingView
DaltonTx, the decision engine for drug discovery, launches advanced AI-powered antibody discovery platform - GlobeNewswire Inc.
AstraZeneca invests USD 2 billion in Summit. AstraZeneca stock falls 1.24 percent. - AD HOC NEWS
AstraZeneca (LSE:AZN) Oncology Filing Puts Valuation and Growth Back in Focus - kalkinemedia.com
700,000 Seniors Have Started GLP-1s Through Medicare. Now AstraZeneca Just Moved a Once-Daily Pill Into Phase 3 - Yahoo Finance
AstraZeneca slips Wednesday, underperforms market - MarketWatch
AstraZeneca's $2 Billion Vote of Confidence Leaves Summit Therapeutics Trading Well Below Street Targets - 247wallst.com
AstraZeneca PLC Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky for More Information – AZN - ACCESS Newswire
AstraZeneca PLC : Deutsche Bank reaffirms its Neutral rating - marketscreener.com
Bone Metastasis in Solid Tumors Market Insights, Epidemiology, and 7MM Forecast - GlobeNewswire Inc.
AstraZeneca to invest $2 billion in Summit Therapeutics for cancer drug tie-up - reuters.com
AstraZeneca files for US FDA approval of HUTCHMED lung cancer drug combination - reuters.com
AstraZeneca PLC (AZN) Stock Down 1.2% -- Now Undervalued? GF Sco - GuruFocus
Astrazeneca (AZN) Registers a Bigger Fall Than the Market: Important Facts to Note - Yahoo Finance Singapore
A $2 Billion Reason Why AstraZeneca Stock Is Down Today - Barchart.com
AstraZeneca submits NDA for savolitinib + Tagrisso for NSCLC - Seeking Alpha
AstraZeneca pours $2bn into Summit to advance cancer treatment - BioXconomy
Summit Shares Jump on $2B Strategic Investment From AstraZeneca - TradingView
AstraZeneca Invests in Summit Therapeutics after Year of Speculation - Benzinga
AstraZeneca invests $2B in Summit, gaining ‘seat at the table’ for PD-1/VEGF drug push - BioPharma Dive
AstraZeneca’s $2 billion Summit stake wins backing from UBS and Jefferies - Proactive financial news
Summit Secures $2 Billion AstraZeneca Investment, Cancer Drug Trial Collaboration - marketscreener.com
Summit Therapeutics Soars Nearly 20% After AstraZeneca Bets $2 Billion on Cancer Drug Ivonescimab - Benzinga
Goldman Sachs reiterates Summit Therapeutics stock rating on AstraZeneca deal - Investing.com
Rights equivalent to a 12% stake await closing as AstraZeneca (AZN) agrees to invest in Summit. - Stock Titan
AstraZeneca to invest $2bn in Summit for ADC combination therapies - Pharmaceutical Technology
Summit soars after $2 billion investment from AstraZeneca for cancer therapies - reuters.com
AstraZeneca PLC : RBC reaffirms its Buy rating - marketscreener.com
AstraZeneca PLC : JP Morgan maintains a Buy rating - marketscreener.com
AstraZeneca invests $2bn in Summit Therapeutics - marketscreener.com
FTSE 100 rises as AstraZeneca lifts healthcare sector - marketscreener.com
AstraZeneca PLC : Deutsche Bank is Neutral - marketscreener.com
AstraZeneca invests £1.5bn into US firm Summit for cancer drug tie-up - uk.finance.yahoo.com
Analysts back AstraZeneca's $2B Summit Therapeutics investment as stock gains (AZN:NYSE) - Seeking Alpha
AstraZeneca invests $2 billion in Summit Therapeutics in cancer drug deal - Proactive financial news
AstraZeneca takes $2bn stake in Summit Therapeutics to pair up cancer drugs - Proactive Investors
AstraZeneca Invests $2bn In Summit To Accelerate Ivonescimab Development - DirectorsTalk Interviews
AstraZeneca to Buy $2 Billion of New Equity in Summit Therapeutics - marketscreener.com
AstraZeneca PLC submits US NDA for Orpathys plus Tagrisso - Mugglehead Investment Magazine
Summit Therapeutics agrees to US$2B AstraZeneca equity investment - Mugglehead Investment Magazine
AstraZeneca files US FDA application for Hutchmed lung cancer drug combination - marketscreener.com
SMMT Stock Soars After-Hours: Did AstraZeneca Just End Summit’s Cash Scare? - Yahoo Finance
AstraZeneca (AZN) is Expanding its Oncology Engine. Can New Growth Offset Legacy Pressure? - Yahoo Finance
Summit Therapeutics Shares Jump as AstraZeneca's Plan to Invest $2 Billion - marketscreener.com
AstraZeneca to invest USD2 billion in Summit Therapeutics - marketscreener.com
Summit shares surge after-hours on $2 billion AstraZeneca equity deal - Yahoo Finance
AstraZeneca Invests $2 Billion in Summit Therapeutics; Enters Clinical Collaboration - marketscreener.com
Finanzdaten der Astrazeneca Plc-Aktie (AZN)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.04%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):